FY2022 EPS Estimates for Axsome Therapeutics, Inc. Decreased by William Blair (NASDAQ:AXSM)

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) – William Blair dropped their FY2022 earnings per share estimates for shares of Axsome Therapeutics in a note issued to investors on Monday, April 25th. William Blair analyst M. Minter now forecasts that the company will earn ($3.85) per share for the year, down from their previous estimate of ($3.73). William Blair also issued estimates for Axsome Therapeutics’ Q4 2022 earnings at ($0.99) EPS, Q1 2023 earnings at ($0.39) EPS, Q2 2023 earnings at ($0.24) EPS, Q3 2023 earnings at ($0.06) EPS, Q4 2023 earnings at $0.14 EPS, FY2023 earnings at ($0.55) EPS and FY2024 earnings at $6.71 EPS.

Other equities analysts also recently issued reports about the company. SVB Leerink decreased their price target on Axsome Therapeutics from $65.00 to $50.00 and set an “outperform” rating for the company in a research note on Wednesday, March 2nd. Zacks Investment Research downgraded Axsome Therapeutics from a “buy” rating to a “hold” rating and set a $32.00 price target for the company. in a research note on Friday, March 4th. Jefferies Financial Group lifted their price target on Axsome Therapeutics from $71.00 to $77.00 and gave the stock a “buy” rating in a research note on Tuesday, March 29th. Finally, StockNews.com started coverage on Axsome Therapeutics in a research note on Thursday, March 31st. They issued a “sell” rating for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $80.78.

NASDAQ:AXSM opened at $30.50 on Thursday. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -8.79 and a beta of 2.41. Axsome Therapeutics has a one year low of $19.38 and a one year high of $74.10. The stock has a 50-day simple moving average of $34.82 and a 200 day simple moving average of $34.55. The company has a debt-to-equity ratio of 3.14, a quick ratio of 3.75 and a current ratio of 3.75.

Axsome Therapeutics (NASDAQ:AXSM – Get Rating) last announced its earnings results on Tuesday, March 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.99) by $0.09. During the same period in the previous year, the business earned ($0.78) EPS.

A number of hedge funds have recently modified their holdings of the business. Atticus Wealth Management LLC bought a new stake in shares of Axsome Therapeutics during the third quarter valued at approximately $30,000. Tortoise Investment Management LLC bought a new stake in shares of Axsome Therapeutics during the fourth quarter valued at approximately $49,000. Nisa Investment Advisors LLC raised its holdings in shares of Axsome Therapeutics by 324.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,078 shares of the company’s stock valued at $57,000 after buying an additional 1,588 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Axsome Therapeutics by 27.7% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,827 shares of the company’s stock valued at $158,000 after buying an additional 831 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC raised its holdings in shares of Axsome Therapeutics by 18.4% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,500 shares of the company’s stock valued at $170,000 after buying an additional 700 shares during the last quarter. Institutional investors own 48.45% of the company’s stock.

About Axsome Therapeutics (Get Rating)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.

Read More